Another possibility is to study the potential use of PGE1 (derived from DGLA) that is similar in structure and action to PGE2 except that it is a platelet anti-aggregator (in addition to its ability to suppress IL-6 and TNF-α synthesis, anti-inflammatory and vasodilator actions) whereas PGE2 is a platelet aggregator in COVID-19, ARDS and sepsis. The gene discussed is TNF; the disease is COVID-19.